Browse Drugs Alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Request Attorney Assistance

Please complete all the fields below to send the bad drug report. Each field is required to be completed in order to send. The submission of this form does not form an attorney client relationship. An attorney client relationship will only be formed after the execution and return of a retainer agreement.

Januvia and Byetta Cases to Be Reviewed by JMDL

Author: Lauren Cohrs
Posted on Jul 9, 2013 in bad-drug-blog

Due to the high volume of lawsuits against manufacturers of incretin mimetics Byetta and Januvia, the Judicial Panel on Multi-District Litigation (JMDL) will meet on July 25th for further review. These type-2 diabetes medications have been linked to adverse reactions of pancreatitis and pancreatic cancer. The JMDL will discuss these reports and information in order to provide consistent rulings for future lawsuits. The hearing will conclude with a decision on whether the cases should shift to a multi-district litigation to be tried.

Incretin Mimetics Byetta and Januvia Linked to Cancers

According to experts, the action of incretin mimetics in the body can augment the risk of developing cancers of the pancreas or thyroid. Incretin mimetics inhibit the enzyme DPP-4 in order to jump-start insulin production. However, DPP-4 enzymes play an essential part in preventing and fighting cancerous cells. As a consequence of blocking the function of these enzymes, patients are left susceptible to the spread of cancerous cells. In addition to this issue, Januvia and Byetta elevate amounts of glucagon-like peptide-1 (GLP-1), often causing rapid growth of pancreatic cells.

The U.S. Food and Drug Administration began investigation of the supposed cancer-inducing reaction in March of 2013. Aside from Januvia (sitagliptin) and Byetta (exenatide), research will also be conducted for similar medicines Victoza (liraglutide) and Onglyza (saxagliptin). The most recent studies conducted by the University of California support the notion that incretin mimetics raise the risks of cancers. The findings of these experiments demonstrate that Januvia and comparable medications can triple the possibility of developing carcinomas.

Byetta and Januvia Lawsuits

Records account for over 53 cases concerning incretin mimetics which have already been taken to court in the United States. Legal action ranges from allegations of neglecting to warn of serious side effects, to wrongful death lawsuits. If the cases do transfer to a multi-district litigation, the consistency of lawsuit data and court rulings can be maintained. This ensure fairness and speediness of trials.

If you or a loved one has been affected by adverse reactions related to type-2 diabetes medications such as Byetta, Januvia, or Victoza, get the legal help you deserve. Submit your information on our “Request Attorney Assistance” form for an evaluation through our expert attorneys.

0."/>